Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Shares Outstanding (Weighted Average) (2018 - 2024)

Historic Shares Outstanding (Weighted Average) for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2024 value amounting to $18.0 million.

  • BioNexus Gene Lab's Shares Outstanding (Weighted Average) rose 711.38% to $18.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $18.0 million, marking a year-over-year increase of 711.38%. This contributed to the annual value of $15.9 million for FY2023, which is 1017.17% up from last year.
  • As of Q3 2024, BioNexus Gene Lab's Shares Outstanding (Weighted Average) stood at $18.0 million, which was up 711.38% from $17.7 million recorded in Q2 2024.
  • In the past 5 years, BioNexus Gene Lab's Shares Outstanding (Weighted Average) registered a high of $173.0 million during Q2 2022, and its lowest value of $14.4 million during Q4 2022.
  • For the 5-year period, BioNexus Gene Lab's Shares Outstanding (Weighted Average) averaged around $83.4 million, with its median value being $102.7 million (2020).
  • Per our database at Business Quant, BioNexus Gene Lab's Shares Outstanding (Weighted Average) surged by 6666.67% in 2021 and then tumbled by 9163.09% in 2023.
  • Over the past 5 years, BioNexus Gene Lab's Shares Outstanding (Weighted Average) (Quarter) stood at $102.9 million in 2020, then surged by 66.36% to $171.2 million in 2021, then tumbled by 91.58% to $14.4 million in 2022, then grew by 10.17% to $15.9 million in 2023, then grew by 13.18% to $18.0 million in 2024.
  • Its last three reported values are $18.0 million in Q3 2024, $17.7 million for Q2 2024, and $17.7 million during Q1 2024.